Sarcopenia as a Determinant of the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: A Meta-Analysis

References

• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
   PubMed Web of Science ®Google Scholar
• Bade BC, Dela Cruz CS. Lung cancer 2020: epidemiology, etiology, and prevention. Clin Chest Med. 2020;41(1):1–24.
   PubMed Web of Science ®Google Scholar
• Rosell R, Karachaliou N. Large-scale screening for somatic mutations in lung cancer[J]. Lancet. 2016;387(10026):1354–6.
   PubMed Web of Science ®Google Scholar
• Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, et al. Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med. 2020;383(10):931–43.
   PubMed Web of Science ®Google Scholar
• Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, KEYNOTE-189 Investigators, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078–92.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, KEYNOTE-407 Investigators, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040–51.
   PubMed Web of Science ®Google Scholar
• Li X, Lian Z, Wang S, Xing L, Yu J. Interactions between EGFR and PD-1/pd-L1 Pathway:implications for Treatment of NSCLC. Cancer Lett. 2018;418:1–9.
   PubMed Web of Science ®Google Scholar
• Mok TSK, Wu Y-L, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G, Srimuninnimit V, Laktionov KK, Bondarenko I, KEYNOTE-042 Investigators, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819–30.
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–65.
   PubMed Web of Science ®Google Scholar
• Nakamura Y. Biomarkers for immune checkpoint inhibitor-mediated tumor response and adverse events. Front Med (Lausanne). 2019;6:119.
   PubMed Web of Science ®Google Scholar
• Schildhaus HU. Predictive value of PD-L1 diagnostics. Pathologe. 2018;39(6):498–519.
   PubMed Web of Science ®Google Scholar
• Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet. 2019;393(10191):2636–46.
   PubMed Web of Science ®Google Scholar
• Bossi P, Delrio P, Mascheroni A, Zanetti M. The spectrum of malnutrition/cachexia/sarcopenia in oncology according to different cancer types and settings: a narrative review. Nutrients. 2021;13(6):1980.
   PubMed Web of Science ®Google Scholar
• Shiroyama T, Nagatomo I, Koyama S, Hirata H, Nishida S, Miyake K, Fukushima K, Shirai Y, Mitsui Y, Takata S, et al. Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: a preliminary retrospective study. Sci Rep. 2019;9(1):2447.
   PubMedGoogle Scholar
• Shachar S, Williams GR, Muss HB, Nishijima TF. Prognostic value of sarcopenia in adults with solid tumours: a meta analysis and systematic review. Eur J Cancer. 2016;57:58–67.
   PubMed Web of Science ®Google Scholar
• Nakamura R, Inage Y, Tobita R, Yoneyama S, Numata T, Ota K, Yanai H, Endo T, Inadome Y, Sakashita S, et al. Sarcopenia in resected NSCLC: effect on postoperative outcomes. J Thorac Oncol. 2018;13(7):895–903.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen P, Huang J, Liu M, Peng D, Li Z, Chen T, Hong S, Zhou Y. Assessment of sarcopenia as a predictor of poor overall survival for advanced non-small-cell lung cancer patients receiving salvage anti-PD-1 immunotherapy. Ann Transl Med. 2021;9(24):1801.
   PubMed Web of Science ®Google Scholar
• Tenuta M, Gelibter A, Pandozzi C, Sirgiovanni G, Campolo F, Venneri MA, Caponnetto S, Cortesi E, Marchetti P, Isidori AM, et al. Impact of sarcopenia and inflammation on patients with advanced non-small cell lung cancer (NCSCL) treated with immune checkpoint inhibitors (ICIs): a prospective study. Cancers (Basel). 2021;13(24):6355.
   PubMed Web of Science ®Google Scholar
• Petrova MP, Donev IS, Radanova MA, Eneva MI, Dimitrova EG, Valchev GN, Minchev VT, Taushanova MS, Boneva MV, Karanikolova TS, et al. Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second-line pembrolizumab in patients with non-small-cell lung cancer. Clin Exp Immunol. 2020;202(3):353–62.
   PubMed Web of Science ®Google Scholar
• Nishioka N, Naito T, Notsu A, Mori K, Kodama H, Miyawaki E, Miyawaki T, Mamesaya N, Kobayashi H, Omori S, et al. Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non-small cell lung cancer. Cancer Med. 2021;10(1):247–56.
   PubMed Web of Science ®Google Scholar
• Rounis K, Makrakis D, Tsigkas A-P, Georgiou A, Galanakis N, Papadaki C, Monastirioti A, Vamvakas L, Kalbakis K, Vardakis N, et al. Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study. Transl Lung Cancer Res. 2021;10(8):3538–49.
   PubMed Web of Science ®Google Scholar
• Tsukagoshi M, Yokobori T, Yajima T, Maeno T, Shimizu K, Mogi A, Araki K, Harimoto N, Shirabe K, Kaira K, et al. Skeletal muscle mass predicts the outcome of nivolumab treatment for non-small cell lung cancer. Medicine (Baltimore). 2020;99(7):e19059.
   PubMed Web of Science ®Google Scholar
• Takada K, Yoneshima Y, Tanaka K, Okamoto I, Shimokawa M, Wakasu S, Takamori S, Toyokawa G, Oba T, Osoegawa A, et al. Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors. J Cancer Res Clin Oncol. 2020;146(5):1217–25.
   PubMed Web of Science ®Google Scholar
• Roch B, Coffy A, Jean-Baptiste S, Palaysi E, Daures J-P, Pujol J-L, Bommart S. Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors. Lung Cancer. 2020;143:19–26.
   PubMed Web of Science ®Google Scholar
• Minami S, Ihara S, Tanaka T, Komuta K. Sarcopenia and visceral adiposity did not affect efficacy of immune-checkpoint inhibitor monotherapy for pretreated patients with advanced non-small cell lung cancer. World J Oncol. 2020;11(1):9–22.
   PubMedGoogle Scholar
• Nishioka N, Uchino J, Hirai S, Katayama Y, Yoshimura A, Okura N, Tanimura K, Harita S, Imabayashi T, Chihara Y, et al. Association of sarcopenia with and efficacy of anti-PD-1/PD-L1 therapy in non-small-cell lung cancer. JCM. 2019;8(4):450.
   Google Scholar
• Magri V, Gottfried T, Di Segni M, Urban D, Peled M, Daher S, Stoff R, Bar J, Onn A. Correlation of body composition by computerized tomography and metabolic parameters with survival of nivolumab-treated lung cancer patients. Cancer Manag Res. 2019;11:8201–7.
   PubMed Web of Science ®Google Scholar
• Cortellini A, Verna L, Porzio G, Bozzetti F, Palumbo P, Masciocchi C, Cannita K, Parisi A, Brocco D, Tinari N, et al. Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: a "hypothesis-generator" preliminary report. Thorac Cancer. 2019;10(2):347–51.
   PubMed Web of Science ®Google Scholar
• Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, et al. Genomic and transcriptomic features of response to Anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165(1):35–44.
   PubMed Web of Science ®Google Scholar
• Deng H-Y, Chen Z-J, Qiu X-M, Zhu D-X, Tang X-J, Zhou Q. Sarcopenia and prognosis of advanced cancer patients receiving immune checkpoint inhibitors: a comprehensive systematic review an meta-analysis. Nutrition. 2021;90:111345.
   PubMed Web of Science ®Google Scholar
• Wang J, Cao L, Xu S. Arcopenia affects clinical efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients: a systematic review and meta-analysis. Int Immunopharmacol. 2020;88:106907.
   PubMed Web of Science ®Google Scholar
• Argilés JM, Busquets S, Stemmler B, López-Soriano FJ. Cachexia and sarcopenia: mechanisms and potential targets for intervention. Curr Opin Pharmacol. 2015;22:100–6.
   PubMed Web of Science ®Google Scholar
• Wiedmer P, Jung T, Castro JP, Pomatto LCD, Sun PY, Davies KJA, Grune T. Sarcopenia - Molecular mechanisms and open questions. Ageing Res Rev. 2021;65:101200.
   PubMed Web of Science ®Google Scholar
• Pratesi A, Tarantini F, Di Bari M. Skeletal muscle: an endocrine organ. Clin Cases Miner Bone Metab. 2013;10(1):11–4.
   PubMedGoogle Scholar
• Suresh K, Psoter KJ, Voong KR, Shankar B, Forde PM, Ettinger DS, Marrone KA, Kelly RJ, Hann CL, Levy B, et al. Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy. J Thorac Oncol. 2019;14(3):494–502.
   PubMed Web of Science ®Google Scholar
• Gomatou G, Tzilas V, Kotteas E, Syrigos K, Bouros D. Immune checkpoint inhibitor-related pneumonitis. Respiration. 2020;99(11):932–42.
   PubMed Web of Science ®Google Scholar
• Kikuchi R, Takoi H, Ishiwari M, Toriyama K, Kono Y, Togashi Y, Abe S. Impact of sarcopenia on chemotherapy-triggered exacerbation of interstitial lung disease in patients with non-small cell lung cancer. Thorac Cancer. 2022;13(4):549–56.
   PubMed Web of Science ®Google Scholar
• Buckinx F, Landi F, Cesari M, Fielding RA, Visser M, Engelke K, Maggi S, Dennison E, Al-Daghri NM, Allepaerts S, et al. Pitfalls in the measurement of muscle mass: a need for a reference standard. J Cachexia Sarcopenia Muscle. 2018;9(2):269–78.
   PubMed Web of Science ®Google Scholar
• Murphy RA, Mourtzakis M, Chu QSC, Baracos VE, Reiman T, Mazurak VC. Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with Non-small cell lung cancer receiving chemotherapy. Cancer. 2011;117(8):1775–82.
   PubMed Web of Science ®Google Scholar
• De Spiegeleer A, Beckwee D, Bautmans I, Petrovic M, the Sarcopenia Guidelines Development group of the Belgian Society of Gerontology and Geriatrics (BSGG). Pharmacological interventions to improve muscle mass, muscle strength and physical performance in older people: an umbrella review of systematic reviews and meta-analyses. Drugs Aging. 2018;35(8):719–34.
   PubMed Web of Science ®Google Scholar
• Rooks D, Praestgaard J, Hariry S, Laurent D, Petricoul O, Perry RG, Lach-Trifilieff E, Roubenoff R. Treatment of sarcopenia with bimagrumab: results from a Phase II, randomized, controlled, proof-of-concept study. J Am Geriatr Soc. 2017;65(9):1988–95.
   PubMed Web of Science ®Google Scholar